QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?
CONCLUSIONS: From a regulatory perspective one cannot refute the possibility of a clinically relevant risk from QT shortening through the current testing requirements. Lack of further investigations into any potential morphological changes to the AP, or APD90 shortening beyond a specified threshold in our opinion does not fully exclude the possibility of proarrhythmic effects of active substances.PMID:35621140 | DOI:10.1080/03007995.2022.2083401
Source: Current Medical Research and Opinion - Category: Research Authors: Amy Tanti Benjamin Micallef Janis Vella Szijj Anthony Serracino-Inglott John-Joseph Borg Source Type: research
More News: Atenolol | Calcium | Carbamazepine | Cardiology | Cardiovascular | Electrocardiogram | France Health | Geodon | Gilenya | Heart | Ibuprofen | Research | Seroquel | Simvastatin | Statin Therapy | Ziprasidone | Zocor | Zyprexa